Feasibility-related reporting characteristics | Indirect Citersa | Citersa | ||||
---|---|---|---|---|---|---|
N = 71 | N = 167 | |||||
Odds ratio | 95% CIb | p-value | Odds ratio | 95% CIb | p-value | |
Feasibility indicators | ||||||
 Recruitment | 0.83 | 0.44–1.54 | 0.544 | 1.78 | 0.97–3.28 | 0.065 |
 Retention | 1.58 | 0.84–2.96 | 0.155 | 3.75 | 1.98–7.13 | < 0.001 |
 Acceptability | 2.39 | 1.29–4.45 | 0.006 | 14.15 | 6.43–31.15 | < 0.001 |
 Adverse events | 1.36 | 0.52–3.55 | 0.531 | 4.38 | 2.07–9.23 | < 0.001 |
 Attendance | 1.51 | 0.70–3.25 | 0.293 | 1.39 | 0.69–2.79 | 0.358 |
 Compliance | 1.35 | 0.74–2.46 | 0.330 | 2.62 | 1.55–4.45 | < 0.001 |
 Cost | 0.91 | 0.22–3.73 | 0.891 | 4.35 | 1.66–11.40 | 0.003 |
 Data collection | 1.01 | 0.33–3.14 | 0.984 | 4.35 | 1.93–9.78 | < 0.001 |
 Treatment fidelity | 2.12 | 1.05–4.29 | 0.036 | 8.82 | 4.73–16.44 | < 0.001 |
Feasibility-related characteristics | ||||||
 Title includes feasibility-related language | 0.72 | 0.39–.34 | 0.303 | 1.51 | 0.82–2.78 | 0.188 |
 Feasibility mentioned in purpose statement | 1.36 | 0.75–2.48 | 0.314 | 9.87 | 4.58–21.23 | < 0.001 |
 Efficacy mentioned in purpose statement | 0.77 | 0.43–1.38 | 0.379 | 0.54 | 0.32–0.91 | 0.020 |
 Progression criteria provided | 1.86 | 0.26–13.51 | 0.539 | 17.04 | 3.91–74.29 | < 0.001 |
 Statistical testing for efficacy | 0.36 | 0.18–0.75 | 0.006 | 0.13 | 0.07–0.26 | < 0.001 |
 Feasibility framed as primary outcome | 1.37 | 0.76–2.48 | 0.296 | 9.66 | 4.63–20.17 | < 0.001 |
 Feasibility of the study mentioned in conclusionc | 1.95 | 0.95–4.03 | 0.070 | 6.31 | 2.43–16.36 | < 0.001 |
 Efficacy of the study mentioned in conclusionc | 0.67 | 0.35–1.28 | 0.223 | 0.50 | 0.26–0.99 | 0.046 |
 Caution advised regarding efficacyc | 1.13 | 0.59–2.18 | 0.716 | 0.61 | 0.31–1.19 | 0.152 |
 Future testing suggestedc | 0.46 | 0.33–1.59 | 0.223 | 0.26 | 0.08–0.84 | 0.024 |